( OTC-PINK:ENTBD, Bloomberg:E9B@GR, Bloomberg:ENTB@US, Bloomberg:ENTBD@US, RICS:ENTBD, ISIN:US29383T1025, OTC-BB:ENTBD )

News from Entest BioMedical, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 29, 2017, 10:09 ET Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders

Entest BioMedical, Inc. (OTC:ENTB) today announced that its Board of Directors has authorized a distribution on a pro rata basis as a dividend in...


Sep 13, 2017, 08:00 ET Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board

Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) announced the appointment of Robin Beat Gasser, DVM, Ph.D. as a...


Jul 26, 2017, 09:45 ET Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators

Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) reported that researchers for Regen BioPharma Inc. have...


Jun 27, 2017, 05:30 ET Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board

Brian Devine, retired Chairman of PETCO, a leading pet specialty retailer, has agreed to serve as Chairman of the Business Advisory Board for...


Jun 13, 2017, 16:00 ET Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies

Entest BioMedical Inc.'s (OTC-PINK: ENTB) subsidiary, Zander Therapeutics, Inc. has tested compounds that act on human cells in suppressing the...


Jun 07, 2017, 08:00 ET Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds

Entest BioMedical Inc.'s (PINK: ENTB) subsidiary, Zander Therapeutics Inc. ,reported that initial data from its canine study suggest that...


May 31, 2017, 08:30 ET Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities

Entest BioMedical Inc. (PINK: ENTB) announced today that it has satisfied $841,531 of Notes Payable as well as $83,000 of accrued expenses through...


May 23, 2017, 10:34 ET Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through Modulation of Checkpoint NR2F6

Entest BioMedical Inc. (PINK: ENTB) and Its subsidiary, Zander Therapeutics Inc., discussed recently reported progress achieved by Regen BioPharma...


Apr 26, 2017, 08:30 ET Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs

Entest BioMedical Inc.'s (OTCPINK: ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company's subsidiary,...


Apr 19, 2017, 08:00 ET Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines

Entest BioMedical Inc.'s (OTCPINK: ENTB) subsidiary, Zander Therapeutics, Inc., has contracted with ChemDiv, Inc., an internationally recognized...


Mar 09, 2017, 08:00 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor

Dr. Donnelly is an Internationally Recognized Animal Researcher, who the Company Believes Will Play an Important Role in the Development of...


Feb 15, 2017, 08:00 ET Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs

Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, Zander Therapeutics Inc., announced today publication by the United States...


Feb 06, 2017, 08:30 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche

Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which...


Feb 06, 2017, 08:30 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche

Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which...


Jan 10, 2017, 08:00 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses

Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its wholly owned subsidiary, Zander Therapeutics, Inc., has filed of a United States...


Dec 21, 2016, 11:25 ET Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017

Entest BioMedical, Inc. (OTCPINK: ENTB)(OTCBB: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for...


Dec 21, 2016, 08:00 ET Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017

Entest BioMedical, Inc. (PINKS: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for Zander...


Nov 18, 2009, 02:00 ET Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) announced today the filing of a third patent application relating to the area of chronic...


May 28, 2009, 10:30 ET New Stem Cell Web Site to Focus on Traumatic Brain Injury, Spinal Cord Injury and Diabetes

Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN)...